Syndax Pharmaceuticals, Inc. Debt Securities, Available-for-sale, Amortized Cost
Syndax Pharmaceuticals, Inc. (SNDX) had Debt Securities, Available-for-sale, Amortized Cost of $238.74 million as of 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Notes
us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis · last filed 2026-08-04
- 2026-06-30: Debt Securities, Available-for-sale, Amortized Cost $238.74M.
- 2026-03-31: Debt Securities, Available-for-sale, Amortized Cost $221.16M.
- 2025-12-31: Debt Securities, Available-for-sale, Amortized Cost $258.69M.
- 2025-09-30: Debt Securities, Available-for-sale, Amortized Cost $338.79M.
| Period end | Debt Securities, Available-for-sale, Amortized Cost |
|---|---|
| 2026-06-30 | $238.74M 10-Q · filed 2026-08-04 |
| 2026-03-31 | $221.16M 10-Q · filed 2026-04-30 |
| 2025-12-31 | $258.69M 10-Q · filed 2026-08-04 |
| 2025-09-30 | $338.79M 10-Q · filed 2025-11-03 |
| 2025-06-30 | $408.94M 10-Q · filed 2025-08-04 |
| 2025-03-31 | $447.62M 10-Q · filed 2025-05-05 |
| 2024-12-31 | $538.16M 10-K · filed 2026-02-26 |
| 2024-09-30 | $266.25M 10-Q · filed 2024-11-05 |
| 2024-06-30 | $350.03M 10-Q · filed 2024-08-01 |
| 2024-03-31 | $428.04M 10-Q · filed 2024-05-08 |
| 2023-12-31 | $304.92M 10-K · filed 2025-03-03 |
| 2023-09-30 | $285.17M 10-Q · filed 2023-11-02 |
| 2023-06-30 | $321.58M 10-Q · filed 2023-08-03 |
| 2023-03-31 | $391.77M 10-Q · filed 2023-05-08 |
| 2022-12-31 | $422.58M 10-K · filed 2024-02-27 |
| 2022-09-30 | $278.06M 10-Q · filed 2022-11-03 |
| 2022-06-30 | $312.00M 10-Q · filed 2022-08-08 |
| 2022-03-31 | $209.80M 10-Q · filed 2022-05-09 |
| 2021-12-31 | $343.07M 10-K · filed 2023-02-28 |
| 2021-09-30 | $168.27M 10-Q · filed 2021-11-15 |
| 2021-06-30 | $185.07M 10-Q · filed 2021-08-09 |
| 2021-03-31 | $206.94M 10-Q · filed 2021-05-11 |
| 2020-12-31 | $182.82M 10-K · filed 2022-03-01 |
| 2020-09-30 | $113.75M 10-Q · filed 2020-11-05 |
| 2020-06-30 | $133.02M 10-Q · filed 2020-08-06 |
| 2020-03-31 | $54.33M 10-Q · filed 2020-05-07 |
| 2019-12-31 | $36.34M 10-K · filed 2021-03-12 |
| 2019-09-30 | $43.63M 10-Q · filed 2019-11-07 |
| 2019-06-30 | $53.80M 10-Q · filed 2019-08-07 |
| 2019-03-31 | $40.13M 10-Q · filed 2019-05-08 |
| 2018-12-31 | $51.67M 10-K · filed 2020-03-05 |
| 2018-09-30 | $63.93M 10-Q · filed 2018-11-05 |
| 2018-06-30 | $71.02M 10-Q · filed 2018-08-08 |
| 2018-03-31 | $85.46M 10-Q · filed 2018-05-09 |
| 2017-12-31 | $108.39M 10-K · filed 2019-03-07 |
| 2017-09-30 | $99.83M 10-Q · filed 2017-11-08 |
| 2017-06-30 | $106.93M 10-Q · filed 2017-08-10 |
| 2017-03-31 | $70.43M 10-Q · filed 2017-05-09 |
| 2016-12-31 | $81.43M 10-K · filed 2018-03-08 |
| 2016-09-30 | $102.71M 10-Q · filed 2016-11-14 |
| 2016-06-30 | $110.82M 10-Q · filed 2016-08-15 |
| 2016-03-31 | $110.25M 10-Q · filed 2016-05-16 |
| 2015-12-31 | $63.28M 10-K · filed 2017-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |